These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39152244)

  • 1. FDA approves IDH1 and IDH2 inhibitor for brain cancer.
    Mullard A
    Nat Rev Drug Discov; 2024 Oct; 23(10):731. PubMed ID: 39152244
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA approves first IDH-targeted glioma drug.
    Nat Biotechnol; 2024 Sep; 42(9):1325. PubMed ID: 39271837
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
    Norsworthy KJ; Luo L; Hsu V; Gudi R; Dorff SE; Przepiorka D; Deisseroth A; Shen YL; Sheth CM; Charlab R; Williams GM; Goldberg KB; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Jun; 25(11):3205-3209. PubMed ID: 30692099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 inhibitor shows promising early results.
    Cancer Discov; 2015 Jan; 5(1):4. PubMed ID: 25583779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
    Sharma H
    Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH Inhibitors Target Common Glioma Mutation.
    Cancer Discov; 2019 Aug; 9(8):992. PubMed ID: 31217295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML.
    Kats LM; Vervoort SJ; Cole R; Rogers AJ; Gregory GP; Vidacs E; Li J; Nagaraja R; Yen KE; Johnstone RW
    Leukemia; 2017 Jun; 31(6):1466-1470. PubMed ID: 28280273
    [No Abstract]   [Full Text] [Related]  

  • 8. IDH2 inhibition in AML: Finally progress?
    Stein EM
    Best Pract Res Clin Haematol; 2015; 28(2-3):112-5. PubMed ID: 26590767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ivosidenib: First Global Approval.
    Dhillon S
    Drugs; 2018 Sep; 78(14):1509-1516. PubMed ID: 30209701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress and predictions: AML in 2018.
    Rowe JM
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):337-340. PubMed ID: 30466743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
    Liu Z; Yao Y; Kogiso M; Zheng B; Deng L; Qiu JJ; Dong S; Lv H; Gallo JM; Li XN; Song Y
    J Med Chem; 2014 Oct; 57(20):8307-18. PubMed ID: 25271760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.
    Cathelin S; Sharon D; Subedi A; Cojocari D; Phillips DC; Leverson JD; MacBeth KJ; Nicolay B; Narayanaswamy R; Ronseaux S; Liu G; Chan SM
    Leukemia; 2022 Mar; 36(3):869-872. PubMed ID: 34743189
    [No Abstract]   [Full Text] [Related]  

  • 13. Large-Scale Drug Screening in Patient-Derived IDH
    Dao Trong P; Jungwirth G; Yu T; Pusch S; Unterberg A; Herold-Mende C; Warta R
    Cells; 2020 Jun; 9(6):. PubMed ID: 32503220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities.
    Huang F; Tian T; Wu Y; Che J; Yang H; Dong X
    Mini Rev Med Chem; 2021; 21(9):1113-1122. PubMed ID: 33256576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA approves first telomerase inhibitor.
    Mullard A
    Nat Rev Drug Discov; 2024 Aug; 23(8):570. PubMed ID: 38877327
    [No Abstract]   [Full Text] [Related]  

  • 16. Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration.
    Cao H; Zhu G; Sun L; Chen G; Ma X; Luo X; Zhu J
    Eur J Med Chem; 2019 Dec; 183():111694. PubMed ID: 31561044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors-Recent Advances, Challenges and Future Prospects.
    Kowalczyk A; Zarychta J; Lejman M; Latoch E; Zawitkowska J
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
    Pusch S; Krausert S; Fischer V; Balss J; Ott M; Schrimpf D; Capper D; Sahm F; Eisel J; Beck AC; Jugold M; Eichwald V; Kaulfuss S; Panknin O; Rehwinkel H; Zimmermann K; Hillig RC; Guenther J; Toschi L; Neuhaus R; Haegebart A; Hess-Stumpp H; Bauser M; Wick W; Unterberg A; Herold-Mende C; Platten M; von Deimling A
    Acta Neuropathol; 2017 Apr; 133(4):629-644. PubMed ID: 28124097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical development of IDH1 inhibitors for cancer therapy.
    Zarei M; Hue JJ; Hajihassani O; Graor HJ; Katayama ES; Loftus AW; Bajor D; Rothermel LD; Vaziri-Gohar A; Winter JM
    Cancer Treat Rev; 2022 Feb; 103():102334. PubMed ID: 34974243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.
    Andronesi OC; Arrillaga-Romany IC; Ly KI; Bogner W; Ratai EM; Reitz K; Iafrate AJ; Dietrich J; Gerstner ER; Chi AS; Rosen BR; Wen PY; Cahill DP; Batchelor TT
    Nat Commun; 2018 Apr; 9(1):1474. PubMed ID: 29662077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.